Navigation Links
Bacterin International Announces Second Quarter and Six Months 2012 Financial Results
Date:8/9/2012

BELGRADE, Mont., Aug. 9, 2012 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, today announced its financial results for the second quarter ended June 30, 2012:

Highlights:

  • Revenue increased 9% to $8.2 million in the second quarter of 2012, compared to the $7.5 million for the same period a year ago.  Excluding a stocking order sale of approximately $1.2 million included in the 2Q 2011 figure, revenues increased from $6.3 million in the 2Q of 2011 to $8.2 million in the 2Q of 2012, an increase of 30%.  
  • The Company reported positive EBITDA of approximately $8,000 and Gross Margin was 72% within the Company's previous guidance of 70 to 75%;
  • Inventory increased 42% to $13.3 million, compared to $9.4 million at the end of 2011, as a result of an increase in the receipt of donor inventory and increased production associated with the Company adding a second production shift during the first quarter of 2012.;
  • The Company exited  its backorder status on a large production push, and  expects increased production to continue throughout the second half of 2012
  • 6 additional product codes were added to address Foot and Ankle, Sports Medicine, and Breast Reconstruction markets.
  • 18 new sales representatives were added and one additional Regional Vice President of Sales in the first half of 2012.
  • The Company has filed 5 new patent applications in the first half of 2012, and continues to pursue 5 patent applications protecting its core products including the patent "Elastomeric Article Having a Broad Spectrum Antimicrobial Agent and Method of Making" which is a composition of matter patent related to our licensing agreement with RyMed Medical
  • A peer review article in Orthopedic Research and Reviews determined OsteoSponge® exhi
    '/>"/>

  • SOURCE Bacterin International Holdings, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss
    2. Bacterin International Signs Its Third National GPO Contract with Novation
    3. Bacterin International Signs Its Fourth National GPO Contract with the Premier healthcare alliance
    4. Bacterin International Holdings, Inc. Schedules Second Quarter 2012 Financial Earnings Conference Call
    5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
    6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
    7. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
    8. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
    9. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
    10. Chindex International, Inc. to Report First Quarter 2012 Financial Results
    11. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... OTTAWA , Dec. 24, 2014 /CNW/ - ... Superburn" is being recalled after Health Canada tests confirmed ... serious health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire ... is recalling the product from retail stores across ... body building purposes, including for weight loss and increased ...
    (Date:12/24/2014)... 24, 2014  Novastem, a leader in regenerative ... in its study for ischemic stroke at Clinica ... ischemic strokes account for 87 percent of all ... in the study, entitled "Internal Research Protocol in ... Stem Cells and Intrathecal Administration of Neural Stem ...
    (Date:12/24/2014)...  Actavis plc (NYSE: ACT ) ... complete response letter from the U.S. Food and ... (NDA) for the fixed-dose combination (FDC) of nebivolol ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... of a complete response letter, Actavis remains committed ...
    Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
    ... CeNeS Pharmaceuticals plc,(LSE: CEN), the Cambridge based biopharmaceutical ... the respected scientific,journal 'Synapse'* on its Phase II ... as a potential treatment for neuropathic,pain. The independent ... undertaken with CNS 5161. , In the study ...
    ... in Humans of CTI's,Programmable, Pulsatile, Passive Transdermal ... TRENTON, N.J., May 03, 2007 /PRNewswire/,-- Chrono ... of its first phase human clinical trial ... ChronoDose(TM). CTI intends to publish this,clinical data ...
    Cached Medicine Technology:Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 2Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 3
    (Date:12/26/2014)... Yisrayl Hawkins, Pastor at The House of Yahweh in Abilene, ... Ferguson, Missouri unrest. Yisrayl starts his letter by showing the ... has only increased. , He continues in his letter ... is a very specific reason for mankind and covers those ... of rules, or Laws that if followed would ensure that ...
    (Date:12/26/2014)... London, England (PRWEB) December 26, 2014 ... to take place March 24-28, 2015 in Rome, Italy ... years' line-up includes workshops on a wide ... insomnia, as well as peak performance training in athletes. ... from around the world. , Biofeedback monitoring allows clients ...
    (Date:12/26/2014)... (PRWEB) December 26, 2014 Plugin and template ... TransPack Volume 5 Plugin for Final Cut Pro X. , ... hard light tool to pull off an industry professional look” ... get their hands on TransPack Volume 5, a new level ... is a set of over 50 Final Cut Pro X ...
    (Date:12/26/2014)... 2014 “Many people become overwhelmed by ... claim issues and phone calls with insurance companies,” The ... featuring their free eBook on pedestrian and bicycle ... pedestrian and bicycle auto accident claims assures the injured ... of professionally handling their case while they focus on ...
    (Date:12/26/2014)... 26, 2014 India Network Foundation, a ... the USA, announced today a new version of “ ... choosing the right plan for their visiting parents. The ... of the selection process when choosing an insurance plan ... with only a few clicks. Many elderly Asian Indian ...
    Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3
    ... report , THURSDAY, April 15 (HealthDay News) -- ... by several common bacteria, including the most virulent form of ... often acquired from oysters which can cause severe illness or ... infection have remained flat in recent years. , "Overall, this ...
    ... says back disorders in the working population are among ... world. Disc degeneration is the main suspected origin of ... surgery. But Videman, a researcher in the University of ... common perception that disc degeneration is caused by physical ...
    ... associated with lower lung function and greater medication use in ... In a paper published online this week in the ... and his colleagues also reported that vitamin D enhances the ... , "Asthmatic children in our study who had low levels ...
    ... ... senior consultant specializing in managed care, prevention planning and publicly funded health care services ... ... to announce that Maureen Hanrahan has joined the company as a senior consultant specializing ...
    ... ... for the amount of $34,000.00. , ... Bedford, MA (PRWEB) April, 15, 2010 -- The law firm of Dussault and Zatir settled out ... was injured while on the job while working as a truck-cleaner. The employee was in ...
    ... condition leaves many undiagnosed, , THURSDAY, April 15 (HealthDay ... detect cases of chlamydia in young men who see ... They say that many urologists are ignoring guidelines on ... which causes inflammation of the testicle and the epididymis, ...
    Cached Medicine News:Health News: E. coli Declines, but Other Foodborne Illnesses a Worry 2Health News: E. coli Declines, but Other Foodborne Illnesses a Worry 3Health News:Low vitamin D levels associated with more asthma symptoms and medication use 2Health News:Hanrahan Joins ArpegioHealth Consulting Firm 2
    For the quantitative in vitro determination of CK-MB in serum and plasma...
    For the quantitative in vitro determination of Cholesterol in serum and plasma....
    For the quantitative in vitro determination of Cholesterol in serum and plasma....
    For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
    Medicine Products: